Page 222 - Drug Class Review
P. 222
Page 141 of 205
Drug Effectiveness Review Project
placebo 75.5 67 92.5 10.2 129 weeks 9.49 Statistically significant benefit of MEM compared to placebo on ADCS-ADL (P = 0.03), NPI (P = Statistically significant benefit of MEM compared to placebo on SIB (P < 0.001), and CIBIC-plus (55% of MEM improved compared to 45% of placebo improved (P = 0.03))
Alzheimer classification: Moderate-severe
Groups similar at baseline: Yes
Health Outcome Measures:
memantine 75.5 63 90.1 9.9 126 weeks 9.25 Primary Outcome Measures: SIB; ADCS-ADL Secondary Outcome Measures: CIBIC-plus; NPI; BGP Timing of assessments: Baseline, and weeks 4, 8, 12, 18 and 24 0.01), and BGP (P = 0.001) Intermediate Outcome Measures:
• •
Final Report Update 1 Authors: Tariot et al. Year: 2004 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Baseline MMSE • Duration of DON treatment • DON dose (mg) • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
